[go: up one dir, main page]

ATE410155T1 - Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung - Google Patents

Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung

Info

Publication number
ATE410155T1
ATE410155T1 AT04701143T AT04701143T ATE410155T1 AT E410155 T1 ATE410155 T1 AT E410155T1 AT 04701143 T AT04701143 T AT 04701143T AT 04701143 T AT04701143 T AT 04701143T AT E410155 T1 ATE410155 T1 AT E410155T1
Authority
AT
Austria
Prior art keywords
inhibitors
breast cancer
cyclin
cancer treatment
treatment
Prior art date
Application number
AT04701143T
Other languages
English (en)
Inventor
Asa Kronblad
Maria Stendahl
Goeran Landberg
Original Assignee
Forskarpatent I Syd Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forskarpatent I Syd Ab filed Critical Forskarpatent I Syd Ab
Application granted granted Critical
Publication of ATE410155T1 publication Critical patent/ATE410155T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04701143T 2003-01-15 2004-01-09 Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung ATE410155T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300098A SE0300098D0 (sv) 2003-01-15 2003-01-15 Use of cyclin D1 inhibitors

Publications (1)

Publication Number Publication Date
ATE410155T1 true ATE410155T1 (de) 2008-10-15

Family

ID=20290133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04701143T ATE410155T1 (de) 2003-01-15 2004-01-09 Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung

Country Status (6)

Country Link
US (1) US20060019883A1 (de)
EP (1) EP1583522B1 (de)
AT (1) ATE410155T1 (de)
DE (1) DE602004016950D1 (de)
SE (1) SE0300098D0 (de)
WO (1) WO2004062654A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1933818A (zh) 2004-01-30 2007-03-21 马尔斯公司 用于治疗癌症的方法和组合物
EP1743654A1 (de) * 2005-07-15 2007-01-17 TopoTarget Germany AG Verwendung von Histon Deacetylase-Hemmer zusammen mit NSAIDen zur Behandlung von Krebs und/oder Entzündungskrankheiten
WO2007061939A2 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
CA2674309A1 (en) 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Preparation of romidepsin
CA2674313A1 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Romidepsin-based treatments for cancer
US20100285002A1 (en) * 2008-01-04 2010-11-11 Immune Disease Institute, Inc. Treatment or prevention of inflammation by targeting cyclin d1
EP2288721B1 (de) * 2008-05-16 2014-05-21 Atlas Antibodies AB Behandlungsprognose mit imgcr-protein
WO2011014825A2 (en) 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
WO2012009336A1 (en) 2010-07-12 2012-01-19 Gloucester Pharmaceuticals, Inc. Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20120208872A1 (en) * 2011-02-11 2012-08-16 Taipei Medical University Use of tea polyphenols for treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer
TWI481398B (zh) * 2011-02-14 2015-04-21 Univ Taipei Medical 茶多酚用於治療及／或預防尼古丁或尼古丁衍生化合物或雌激素誘發之乳癌之用途
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
WO2023211888A1 (en) * 2022-04-25 2023-11-02 Delta Next-Gene, LLC Methods of treating cancer by targeting drivers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410061B1 (en) * 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins as cancer specific proliferation inhibitors

Also Published As

Publication number Publication date
EP1583522A1 (de) 2005-10-12
US20060019883A1 (en) 2006-01-26
WO2004062654A1 (en) 2004-07-29
EP1583522B1 (de) 2008-10-08
DE602004016950D1 (de) 2008-11-20
SE0300098D0 (sv) 2003-01-15

Similar Documents

Publication Publication Date Title
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE50310516D1 (de) Fredericamycin-derivate
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
ATE323474T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
BRPI0413574A (pt) aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ATE411981T1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
DK1653964T3 (da) Cancerkombinationsterapi omfattende AZD2171 og ZD1839
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties